跳至主要内容
临床试验/NCT00081627
NCT00081627已完成2 期

COFU: A Multi-Center Phase II Clinical Trial to Evaluate the Safety and Efficacy of Weekly Treatment With CoFactor and 5-Fluorouracil in Patients With Metastatic Colorectal Carcinoma

Mast Therapeutics, Inc.18 个研究点 分布在 3 个国家目标入组 48 人开始时间: 2004年4月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
48
试验地点
18

研究概览

简要总结

The objectives of this trial are to determine if CoFactor in combination with 5-FU are effective in the treatment of metastatic colorectal cancer and to determine the side effects observed with the administration of CoFactor and 5-FU.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients must have surgically incurable colon or rectal adenocarcinoma
  • Karnofsky Performance Status of 60% or greater
  • Patients may have symptomatic neuropathy
  • Patients must have a life expectancy of at least 4 months
  • Patients must be alimenting, receiving at least 1500Kcal/day nutrition, by any route
  • Patients must have bidimensional measurable disease for response assessment
  • Patients may have received adjuvant chemotherapy with fluoropyrimidine therapy
  • Patients must have recovered from the toxicities of prior therapy, at least 4 weeks since prior adjuvant chemotherapy and major surgery
  • Serum creatinine less than 2.4mg%, serum bilirubin less than 3.0mg%, WBC greater than 3,200/mm2, AGC greater than 1,500/mm3, platelet count greater than 90,000/mm3 and SGOT (AST) and SGPT (ALT) less than 3 times the upper limit of normal
  • Male and non-pregnant, non-lactating female patients must be >18 years old.

排除标准

  • Concurrent infection
  • Failure of the patient or the patient's legal representative to sign the Informed consent
  • Inability to obtain Informed Consent because of psychiatric or complex medical problem
  • Patients with unstable oncologic emergency
  • Patients with unstable medical conditions such as angina, transient ischemic attacks, rising creatinine, accelerated hypertension, etc.
  • Cerebellar neurologic syndromes such as Parkinson's Disease, multiple sclerosis and amyotonia
  • Known intolerance to fluoropyrimidine therapy suggestive of dihydropyrimidine dehydrogenase deficiency.

研究者

申办方类型
Industry

研究点 (18)

Loading locations...

相似试验